Tuberculosis causes 2 million deaths worldwide annually, and development of an effective vaccine is a critical research goal. CFP10 is a secreted M. tuberculosis protein which stimulates T-cells to produce IFN-y and exhibit cytotoxic T lymphocyte activity. Our preliminary data demonstrate that CFP1071-90 is recognized by a high percentage of persons with latent tuberculosis infection, and that it contains at least two epitopes that are recognized by persons expressing different HLA class I and class II alleles. The presence of multiple epitopes, recognized in the context of several HLA molecules, makes CFP1071-90 an attractive vaccine candidate. We will evaluate the immunogenicity and protective capacity of CFP1071-90 through the following aims: 1) Compare the immunogenicity of systemic and mucosal immunization with a DNA vaccine encoding CFP1071-90 in transgenic mice expressing human HLA class I and class II alleles. This will be achieved by immunizing transgenic mice expressing DRB1*0401, A*0201 or both molecules, with a DNA vaccine encoding CFP1071-90. Lung and splenocyte T-cell subpopulations will be characterized by cell surface phenotype and by functional capacity to exhibit CTL activity, and produce IFN-y. (2) Determine the protective efficacy of a DNA vaccine encoding CFP1071-90 in transgenic mice expressing HLA class I and class II alleles. The capacity of the vaccines to reduce the bacillary burden and lung pathology in M. tuberculosis-infected mice will be determined. This proposal will evaluate the efficacy in vivo of a very promising candidate for inclusion in an antituberculosis subunit vaccine. As far as we are aware, this represents the first use of a vaccine expressing a short microbial peptide that stimulates CD4+ and CD8+ T-cells in animals expressing human class I and class II HLA molecules. These studies will provide the opportunity to determine the relative importance of CD4+ and CD8+ T-cells in immunity against M. tuberculosis in a humanized experimental system. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI064898-01A1
Application #
7036404
Study Section
Special Emphasis Panel (ZRG1-VMD (01))
Program Officer
Lacourciere, Karen A
Project Start
2006-03-01
Project End
2008-02-29
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
1
Fiscal Year
2006
Total Cost
$196,875
Indirect Cost
Name
University of Texas Health Center at Tyler
Department
Microbiology/Immun/Virology
Type
Other Domestic Higher Education
DUNS #
800772337
City
Tyler
State
TX
Country
United States
Zip Code
75708
Klucar, Peter; Barnes, Peter F; Kong, Ying et al. (2009) Vaccination strategies to enhance local immunity and protection against Mycobacteriun tuberculosis. Vaccine 27:1816-24
Klucar, Peter; Barnes, Peter F; Kong, Ying et al. (2008) Characterization of effector functions of human peptide-specific CD4+ T-cell clones for an intracellular pathogen. Hum Immunol 69:475-83